Special Report

Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic

https://orcid.org/0000-0001-6779-8713

Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada

Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, H3C 3J7, Canada

Search for more papers by this author

Philippe Huot

*Author for correspondence: Tel.: +1 514 398 8385;

E-mail Address: philippe.huot@mcgill.ca

https://orcid.org/0000-0002-5464-8334

Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada

Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, H3C 3J7, Canada

Department of Neurology & Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada

Department of Neuroscience, Division of Neurology, McGill University Health Centre, Montreal, QC, H3A 2B4, Canada

Search for more papers by this author

Published Online:19 May 2022https://doi.org/10.2217/nmt-2021-0055

View article

Abstract

Levodopa is the standard treatment for Parkinson’s disease, but its use is marred by the emergence of dyskinesia, for which treatment options remain limited. Here, we review the glutamatergic modulators that were assessed for their antidyskinetic potential in clinical trials, including N-methyl-D-aspartate (NMDA) antagonists, agonists at the glycine-binding site on NMDA receptors, metabotropic glutamate (mGlu) 4 agonists, mGlu₅ antagonists, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonists and glutamate release inhibitors. Several agents that were investigated are not selective for their targets, raising uncertainty about the extent to which glutamatergic modulation contributed to their effects. Except for amantadine, the use of glutamatergic modulators for the treatment of dyskinesia in Parkinson’s disease remains largely investigational, with promising results obtained with mGlu₅ negative allosteric modulation.

Plain language summary

Long-term treatment of Parkinson’s disease results in abnormal involuntary movements called ‘dyskinesia’. The chemical substance ‘glutamate’ is deeply involved in the normal functioning of the brain and the drug amantadine, which is used in the clinic to alleviate dyskinesia, is believed to elicit its effects through modulation of glutamate within the brain. In addition to amantadine, several drugs that interact with glutamate have been tested in the clinic, with variable efficacy. Here, we aim to review the pharmacological mechanisms of these drugs and to discuss their efficacy, or lack thereof, in the treatment of dyskinesia in Parkinson’s disease.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 153(6), 1194–1217 (2013).
Medline CASGoogle Scholar
2. Kaeberlein M, Rabinovitch PS, Martin GM. Healthy aging: the ultimate preventative medicine. Science 350(6265), 1191–1193 (2015).
Medline CASGoogle Scholar
3. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 28(3), 311–318 (2013).
MedlineGoogle Scholar
4. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 5(6), 525–535 (2006).
MedlineGoogle Scholar
5. Fox SH, Katzenschlager R, Lim SY et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 33(8), 1248–1266 (2018). • Latest guidelines of the International Parkinson and Movement Disorder Society, notably highlighting recommendations for the treatment of levodopa-induced dyskinesia.
Medline CASGoogle Scholar
6. Seppi K, Ray Chaudhuri K, Coelho M et al. Update on treatments for nonmotor symptoms of Parkinson's disease – an evidence‐based medicine review. Mov. Disord. 34(2), 180–198 (2019).
MedlineGoogle Scholar
7. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 8(10), 929–937 (2009).
Medline CASGoogle Scholar
8. Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease: an update. CNS Drugs 34(10), 1025–1044 (2020).
Medline CASGoogle Scholar
9. de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurol. 19(5), 452–461 (2020).
Medline CASGoogle Scholar
10. Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin. Geriatr. Med. 36(1), 105–118 (2020).
MedlineGoogle Scholar
11. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20(2), 190–199 (2005).
MedlineGoogle Scholar
12. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch. Neurol. 63(2), 205–209 (2006).
MedlineGoogle Scholar
13. Tambasco N, Simoni S, Marsili E et al. Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis. 2012, 745947 (2012).
MedlineGoogle Scholar
14. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498–2508 (2004).
MedlineGoogle Scholar
15. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9(9), 665–677 (2008).
Medline CASGoogle Scholar
16. Bastide MF, Meissner WG, Picconi B et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog. Neurobiol. 132, 96–168 (2015).
Medline CASGoogle Scholar
17. Fox SH, Katzenschlager R, Lim SY et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl. 3), S2–S41 (2011).
MedlineGoogle Scholar
18. Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J. Neural. Transm. (Vienna) 125(8), 1237–1250 (2018).
Medline CASGoogle Scholar
19. Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 20(12), 1048–1056 (2021).
Medline CASGoogle Scholar
20. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75(1), 141–143 (2004).
Medline CASGoogle Scholar
21. Riederer P, Lange KW, Kornhuber J, Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338(8773), 1022–1023 (1991).
Medline CASGoogle Scholar
22. Birkmayer W, Hornykiewicz O. [The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr 73, 787–788 (1961).
Medline CASGoogle Scholar
23. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism – chronic treatment with L-dopa. N. Engl. J. Med. 280(7), 337–345 (1969).
Medline CASGoogle Scholar
24. Oertel W, Eggert K, Pahwa R et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov. Disord. 32(12), 1701–1709 (2017). • Phase III clinical trial that demonstrates the efficacy of amantadine for the treatment of levodopa-induced dyskinesia.
Medline CASGoogle Scholar
25. Pahwa R, Tanner CM, Hauser RA et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov. Disord. 30(6), 788–795 (2015). • Phase II/III clinical trial that shows the efficacy of amantadine for the treatment of levodopa-induced dyskinesia.
Medline CASGoogle Scholar
26. Pahwa R, Tanner CM, Hauser RA et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol. 74(8), 941–949 (2017). • Phase III clinical trial that demonstrates the efficacy of amantadine for the treatment of levodopa-induced dyskinesia.
MedlineGoogle Scholar
27. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51(1), 203–206 (1998).
Medline CASGoogle Scholar
28. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord. 13(3), 414–417 (1998).
Medline CASGoogle Scholar
29. Fox SH, Metman LV, Nutt JG et al. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 32(6), 893–903 (2017). • Phase II clinical trial that provides preliminary evidence of the antidyskinetic potential of dextromethorphan/quinidine for the treatment of levodopa-induced dyskinesia.
Medline CASGoogle Scholar
30. Blanchet PJ, Metman LV, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov. Disord. 11(5), 580–581 (1996).
Medline CASGoogle Scholar
31. Tison F, Keywood C, Wakefield M et al. A phase IIA trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 31(9), 1373–1380 (2016). • Phase IIa trial with dipraglurant, in which it alleviated levodopa-induced dyskinesia, paving the way for the currently ongoing phase IIb/III trial.
Medline CASGoogle Scholar
32. Gelfin E, Kaufman Y, Korn-Lubetzki I et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int. J. Neuropsychopharmacol. 15(4), 543–549 (2012).
Medline CASGoogle Scholar
33. Doller D, Bespalov A, Miller R, Pietraszek M, Kalinichev M. A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model? Expert Opin. Investig. Drugs 29(12), 1323–1338 (2020).
Medline CASGoogle Scholar
34. Montastruc JL, Rascol O, Senard JM, Rascol A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55(7), 630–631 (1992).
Medline CASGoogle Scholar
35. Sherman SJ, Estevez M, Magill AB, Falk T. Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing l-DOPA-induced dyskinesias. Case Rep. Neurol. 8(1), 53–58 (2016). • Case reports highlighting the potential antidyskinetic efficacy of ketamine infusions.
MedlineGoogle Scholar
36. Berg D, Godau J, Trenkwalder C et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26(7), 1243–1250 (2011).
MedlineGoogle Scholar
37. Stocchi F, Rascol O, Destee A et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28(13), 1838–1846 (2013).
Medline CASGoogle Scholar
38. Trenkwalder C, Stocchi F, Poewe W et al. Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase II studies. Mov. Disord. 31(7), 1054–1058 (2016).
Medline CASGoogle Scholar
39. Kumar R, Hauser RA, Mostillo J et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int. J. Neurosci. 126(1), 20–24 (2016).
Medline CASGoogle Scholar
40. Vidal EI, Fukushima FB, Valle AP, Villas Boas PJ. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. J. Am. Geriatr. Soc. 61(1), 170–172 (2013).
MedlineGoogle Scholar
41. Hanagasi HA, Kaptanoglu G, Sahin HA, Emre M. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. Mov. Disord. 15(5), 1016–1017 (2000).
Medline CASGoogle Scholar
42. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson's disease. Mov. Disord. 25(4), 508–510 (2010).
MedlineGoogle Scholar
43. Moreau C, Delval A, Tiffreau V et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J. Neurol. Neurosurg. Psychiatry 84(5), 552–555 (2013).
MedlineGoogle Scholar
44. Wictorin K, Widner H. Memantine and reduced time with dyskinesia in Parkinson's Disease. Acta Neurol. Scand. 133(5), 355–360 (2016).
Medline CASGoogle Scholar
45. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin. Neuropharmacol. 22(5), 273–276 (1999).
Medline CASGoogle Scholar
46. Rascol O, Ferreira J, Negre-Pages L et al. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundam. Clin. Pharmacol. 26(4), 557–564 (2012).
Medline CASGoogle Scholar
47. Corvol JC, Durif F, Meissner WG et al. Naftazone in advanced Parkinson's disease: an acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat. Disord. 60, 51–56 (2019). • Recent phase II trial in which naftazone failed to reduce levodopa-induced dyskinesia.
MedlineGoogle Scholar
48. Lees A, Fahn S, Eggert KM et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease. Mov. Disord. 27(2), 284–288 (2012).
Medline CASGoogle Scholar
49. Eggert K, Squillacote D, Barone P et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov. Disord. 25(7), 896–905 (2010).
MedlineGoogle Scholar
50. Parkinson Study G. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch. Neurol. 58(10), 1660–1668 (2001).
MedlineGoogle Scholar
51. Shoulson I, Penney J, McDermott M et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56(4), 455–462 (2001).
Medline CASGoogle Scholar
52. Clarke CE, Cooper JA, Holdich TA, Group TS. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin. Neuropharmacol. 24(3), 133–138 (2001).
Medline CASGoogle Scholar
53. Wang WW, Zhang XR, Zhang ZR et al. Effects of mGluR5 antagonists on Parkinson's patients with L-Dopa-induced dyskinesia: a systematic review and meta-analysis of randomized controlled trials. Front. Aging Neurosci. 10, 262 (2018).
MedlineGoogle Scholar
54. Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin. Neuropharmacol. 27(1), 25–29 (2004).
Medline CASGoogle Scholar
55. Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov. Disord. 21(9), 1380–1383 (2006).
MedlineGoogle Scholar
56. Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 20(4), 452–455 (2014).
MedlineGoogle Scholar
57. Nutt JG, Gunzler SA, Kirchhoff T et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 23(13), 1860–1866 (2008).
MedlineGoogle Scholar
58. Calon F, Morissette M, Ghribi O et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(1), 127–138 (2002).
Medline CASGoogle Scholar
59. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14(3), 404–416 (2003).
Medline CASGoogle Scholar
60. Ouattara B, Hoyer D, Grégoire L et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 167(4), 1160–1167 (2010).
Medline CASGoogle Scholar
61. Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson's disease. J. Neurochem. 114(2), 499–511 (2010).
Medline CASGoogle Scholar
62. Silverdale MA, Kobylecki C, Hallett PJ et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate. Synapse 64(2), 177–180 (2010).
Medline CASGoogle Scholar
63. Ba M, Kong M, Yang H et al. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats. Neurochem. Res. 31(11), 1337–1347 (2006).
Medline CASGoogle Scholar
64. Santini E, Valjent E, Usiello A et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27(26), 6995–7005 (2007).
Medline CASGoogle Scholar
65. Ouattara B, Hoyer D, Grégoire L et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 167(4), 1160–1167 (2010).
Medline CASGoogle Scholar
66. Konitsiotis S, Blanchet P, Verhagen L, Lamers E, Chase T. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54(8), 1589–1595 (2000).
Medline CASGoogle Scholar
67. Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov. Disord. 26(13), 2354–2363 (2011).
MedlineGoogle Scholar
68. Bibbiani F, Oh J, Kielaite A, Collins M, Smith C, Chase T. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 196(2), 422–429 (2005).
Medline CASGoogle Scholar
69. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol. Scand. Suppl. 197, 19–24 (2013).
Google Scholar
70. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. 19(6), 1294–1308 (1997).
Medline CASGoogle Scholar
71. Rascol O, Barone P, Behari M et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35(1), 15–20 (2012).
Medline CASGoogle Scholar
72. Goetz CG, Stebbins GT, Chung KA et al. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: a randomized, double-blind, placebo-controlled multicenter study. Mov. Disord. 32(9), 1335–1336 (2017).
Medline CASGoogle Scholar
73. Hallett PJ, Dunah A, Ravenscroft P et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48(4), 503–516 (2005).
Medline CASGoogle Scholar
74. Gardoni F, Picconi B, Ghiglieri V et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci. 26(11), 2914–2922 (2006).
Medline CASGoogle Scholar
75. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13(5), 798–802 (1998).
Medline CASGoogle Scholar
76. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50(5), 1323–1326 (1998).
Medline CASGoogle Scholar
77. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9(3), 275–308 (2003).
Medline CASGoogle Scholar
78. Palmer GC, Murray RJ, Wilson TC et al. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res. 12(1), 9–20 (1992).
Medline CASGoogle Scholar
79. Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp. Neurol. 207(2), 248–257 (2007).
Medline CASGoogle Scholar
80. Pope LE, Khalil M, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J. Clin. Pharmacol. 44(10), 1132–1142 (2004).
Medline CASGoogle Scholar
81. Zanos P, Moaddel R, Morris PJ et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol. Rev. 70(3), 621–660 (2018).
Medline CASGoogle Scholar
82. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol. Rev. 65(1), 171–222 (2013).
Medline CASGoogle Scholar
83. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents–preclinical studies. Neurosci. Biobehav. Rev. 21(4), 455–468 (1997).
Medline CASGoogle Scholar
84. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 306(1-2), 81–84 (2001).
Medline CASGoogle Scholar
85. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 312(3), 1195–1205 (2005).
Medline CASGoogle Scholar
86. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 62(2), 149–153 (2008).
Medline CASGoogle Scholar
87. Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur. J. Neurosci. 19(8), 2212–2220 (2004).
MedlineGoogle Scholar
88. Matsubayashi H, Swanson KL, Albuquerque EX. Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J. Pharmacol. Exp. Ther. 281(2), 834–844 (1997).
Medline CASGoogle Scholar
89. Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C. The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology 62(4), 1708–1716 (2012).
Medline CASGoogle Scholar
90. Shen W, Ren W, Zhai S et al. Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine. J. Clin. InvestM 130(5), 2593–2601 (2020).
Medline CASGoogle Scholar
91. Chenard BL, Bordner J, Butler TW et al. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. 38(16), 3138–3145 (1995).
Medline CASGoogle Scholar
92. Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr. Drug Target 2(3), 285–298 (2001).
Medline CASGoogle Scholar
93. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12(1), 64–82 (2013).
Medline CASGoogle Scholar
94. Bogenpohl J, Galvan A, Hu X, Wichmann T, Smith Y. Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex. Neuropharmacology 66, 242–252 (2013).
Medline CASGoogle Scholar
95. Bennouar K-E, Uberti MA, Melon C et al. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 66, 158–169 (2013).
Medline CASGoogle Scholar
96. Iderberg H, Maslava N, Thompson AD et al. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology 95, 121–129 (2015).
Medline CASGoogle Scholar
97. Charvin D, Di Paolo T, Bezard E et al. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. Mov. Disord. 33(10), 1619–1631 (2018).
Medline CASGoogle Scholar
98. Charvin D. mGlu4 allosteric modulation for treating Parkinson's disease. Neuropharmacology 135, 308–315 (2018).
Medline CASGoogle Scholar
99. Pisani A, Gubellini P, Bonsi P et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106(3), 579–587 (2001).
Medline CASGoogle Scholar
100. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 20(21), 7871–7879 (2000).
Medline CASGoogle Scholar
101. Ouattara B, Grégoire L, Morissette M et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol. Aging 32(7), 1286–1295 (2011).
Medline CASGoogle Scholar
102. Bezard E, Pioli EY, Li Q et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov. Disord. 29(8), 1074–1079 (2014).
Medline CASGoogle Scholar
103. Levandis G, Bazzini E, Armentero M-T, Nappi G, Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol. Dis. 29(1), 161–168 (2008).
Medline CASGoogle Scholar
104. Rylander D, Iderberg H, Li Q et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 39(3), 352–361 (2010).
Medline CASGoogle Scholar
105. Grégoire L, Morin N, Ouattara B et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord. 17(4), 270–276 (2011).
MedlineGoogle Scholar
106. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69(3), 318–326 (2006).
Medline CASGoogle Scholar
107. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333(3), 865–873 (2010).
Medline CASGoogle Scholar
108. Stocchi F, Rascol O, Destee A et al. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study. Mov. Disord. 28(13), 1838–1846 (2013).
Medline CASGoogle Scholar
109. Campanelli F, Natale G, Marino G, Ghiglieri V, Calabresi P. Striatal glutamatergic hyperactivity in Parkinson's disease. Neurobiol. Dis. 168, 105697 (2022).
Medline CASGoogle Scholar
110. Mattei C, Molgo J, Joseph X, Israel M, Bloy C. Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes. Neurosci. Lett. 271(3), 183–186 (1999).
Medline CASGoogle Scholar
111. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci. Ther. 17(1), 4–31 (2011).
Medline CASGoogle Scholar
112. Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet 353(9166), 1764–1765 (1999).
Medline CASGoogle Scholar
113. Picconi B, Pisani A, Centonze D et al. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125(Pt 12), 2635–2645 (2002).
MedlineGoogle Scholar
114. Cenci MA. Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease. Biochem. Soc. Trans. 42(2), 600–604 (2014).
Medline CASGoogle Scholar
115. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 64(1), 20–24 (2007).
MedlineGoogle Scholar
116. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal ‘hyperdirect’ pathway. Neurosci. Res. 43(2), 111–117 (2002).
MedlineGoogle Scholar
117. Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav. 79(3), 391–400 (2004).
Medline CASGoogle Scholar
118. Kwan C, Frouni I, Bedard D et al. 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review. Exp. Brain Res. 237(2), 435–442 (2019).
Medline CASGoogle Scholar
119. Kwan C, Nuara SG, Bedard D et al. Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset. Neuropharmacology 182, 108386 (2021).
Medline CASGoogle Scholar
120. Johnston TH, Huot P, Fox SH et al. TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73C, 337–347 (2013).
Google Scholar
121. Rascol O, Arnulf I, Peyro-Saint Paul H et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16(4), 708–713 (2001).
Medline CASGoogle Scholar
122. AlShimemeri S, Fox SH, Visanji NP. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update. Expert Opin. Emerg. Drugs 25(2), 131–144 (2020).
Medline CASGoogle Scholar
123. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2), 87–96 (1996).
Medline CASGoogle Scholar
124. Durif F, Debilly B, Galitzky M et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62(3), 381–388 (2004).
Medline CASGoogle Scholar

Vol. 12, No. 4

Metrics

Downloaded 158 times

History

Received 10 December 2021

Accepted 9 May 2022

Published online 19 May 2022

Published in print August 2022

Information

Keywords

Financial & competing interests disclosure

I Frouni holds a scholarship from Parkinson Canada. P Huot has research support from Parkinson Canada, Fonds de Recherche Québec – Santé, the Natural Sciences and Engineering Research Council of Canada, Parkinson Québec, Healthy Brains for Healthy Lives, the Weston Brain Institute and the Michael J Fox Foundation for Parkinson’s Research. P Huot has received payments from Neurodiem, AbbVie, adMare BioInnovations and Sanford Burnham Prebys. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download